Ceftazidime and Hydrea drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ceftazidime (ceftazidime) and Hydrea (hydroxyurea). Common drug interactions include neutropenic sepsis among females and posterior reversible encephalopathy syndrome among males.

The phase IV clinical study analyzes what interactions people have when they take Ceftazidime and Hydrea. It is created by eHealthMe based on reports of 24 people who take the same drugs from the FDA, and is updated regularly.

What is Ceftazidime?

Ceftazidime has active ingredients of ceftazidime. eHealthMe is studying from 10,327 Ceftazidime users. Check the latest studies of Ceftazidime.

What is Hydrea?

Hydrea has active ingredients of hydroxyurea. It is often used in polycythemia vera. eHealthMe is studying from 9,083 Hydrea users. Check the latest studies of Hydrea.

On Jul, 10, 2026

24 people who take Ceftazidime and Hydrea together, and have interactions are studied.

Ceftazidime and Hydrea drug interactions.

What are the common drug interactions of Ceftazidime and Hydrea, by gender? *:

female:

Neutropenic sepsis (whole body infection is caused by a condition in which the number of white blood cells (called neutrophils) in the blood is low. neutrophils help the body to fight infection)
Respiratory failure (inadequate gas exchange by the respiratory system)

male:

Posterior reversible encephalopathy syndrome (posterior reversible encephalopathy syndrome (pres), also known as reversible posterior leukoencephalopathy syndrome (rpls), is a syndrome characterized by headache, confusion, seizures and visual loss)
Cytokine release syndrome (immediate complication occurring with the use of anti-t cell antibody infusions)
Eye movement disorder
Liver disorder (liver diseases)
Lymphadenitis (inflammation or enlargement of a lymph node)
Mydriasis (a dilation of the pupil)
Sinus bradycardia (an unusually slow heartbeat due to heart disease)
Thrombocytopenia (decrease of platelets in blood)
Ventricular fibrillation (abnormally irregular heart rhythm)
Decreased appetite

What are the common drug interactions of Ceftazidime and Hydrea, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Cytokine release syndrome (immediate complication occurring with the use of anti-t cell antibody infusions)
Infusion related reaction
Bronchopulmonary aspergillosis (lung disorder caused by aspergillus fungi)
Cardio-respiratory arrest (sudden dysfunction of heart and lungs)
Cerebellar syndrome (impaired blood circulation to cerebellum due to lesion in artery)
Coma (state of unconsciousness lasting more than six hours)
Confusional state
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body)
Eye movement disorder
Liver disorder (liver diseases)

20-29:

n/a

30-39:

n/a

40-49:

Posterior reversible encephalopathy syndrome (posterior reversible encephalopathy syndrome (pres), also known as reversible posterior leukoencephalopathy syndrome (rpls), is a syndrome characterized by headache, confusion, seizures and visual loss)

50-59:

Hepatic fibrosis (scarring process that represents the liver's response to injury)
Neutropenic sepsis (whole body infection is caused by a condition in which the number of white blood cells (called neutrophils) in the blood is low. neutrophils help the body to fight infection)
Respiratory failure (inadequate gas exchange by the respiratory system)
Blood bilirubin increased
Cholestasis (a condition where bile cannot flow from the liver to the duodenum)

60+:

Blood lactate dehydrogenase increased
Thrombocytopenia (decrease of platelets in blood)
Decreased appetite
Malaise (a feeling of general discomfort or uneasiness)
Pyrexia (fever)
White blood cell count increased

What are the existing conditions these people have? *

Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 18 people, 75.00%
Stress And Anxiety: 12 people, 50.00%
Infection: 12 people, 50.00%
Fever: 3 people, 12.50%
Essential Thrombocythaemia (chronic blood cancer): 2 people, 8.33%
Bronchopulmonary Aspergillosis (lung disorder caused by aspergillus fungi): 2 people, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Ceftazidime and Hydrea?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously